The study was performed on 48 subjects divided into four groups: contr
ol (1), hypercholesterolemia (2), hypertriglyceridemia (3) and mixed h
yperlipidemia (4). The concentration and pharmacokinetic parameters fo
r total phenytoin were determined after a single oral dose of 300 mg.
Hypercholesterolemia (HCh) and mixed hyperlipidemia (MI-IL) significan
tly influenced the pharmacokinetics of total phenytoin, while hypertri
glyceridemia (HTG) was without effect. The mean serum concentration of
phenytoin was significantly higher in the HCh and MHL groups as compa
red with the control from 12 to 72 h. A significant increase in AUC, a
nd t(max) was observed in the HCh group. No significant changes were f
ound in the HTG group. In the MHL group, AUC increased and CL/F/BW dec
reased. It was shown that hypercholesterolemia and mixed hyperlipidemi
a change the pharmacokinetics of phenytoin.